# Trade Mark Journal No.2026/014 3 April 2026

## WO0000001893722 (42,44)

Office of origin: United States of America

Date of International Registration:2 July 2025
Date of designation in the UK: 2 July 2025

The mark consists of the shape of a shield with three arched, half-concentric, curved lines within the shield shape; the wording CARIS LIFE SCIENCES are located to the right side of the shield with the "A" in the word CARIS being stylized; the word "CARIS" is over the wording "LIFE SCIENCES".

International priority date claimed: 16 January 2025 (United States of America) (99000412)

Class 42
  Medical and scientific research; medical and scientific research services in the fields of anatomic pathology, molecular profiling, blood-based diagnostics, oncology, genomics, and proteomics; pharmaceutical research and development; genetic and proteomic research studies of specimens; genetic and proteomic research studies of specimens, namely, next-generation sequencing, whole exome sequencing, whole transcriptome sequencing, whole genome sequencing, mass spectrometry, genetic signatures, specific genetic targets, DNA/RNA isolation and western blot analysis, facilitating effective clinical trials, product development, and research using large amounts of biospecimens and associated research and patient data; providing medical and scientific research in the fields of oncology, and molecular profiling, genomics and proteomics; conducting clinical trials; medical research laboratory services; medical research laboratory services, namely, analysis of individualized patient data to aid physicians in determining diagnostic, therapeutic and prognostic objectives for patients; medical research laboratory services, namely, providing patient reports based on analysis of RNA, DNA and protein to aid physicians in determining diagnosis, including screening and early detection, prognosis, and predicting or monitoring residual disease, recurrence and/or therapeutic response for cancer patients; providing a centralized database in the field of molecular diagnostics to allow oncologists to acquire and share molecular tumor profiling information and clinical outcomes within a collaborative, secured environment, all for treatment and diagnostic purposes (terms considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations).
Class 44
  Medical screening services; medical diagnostic testing, monitoring and reporting services; pathology diagnostic services; prognostic analysis services; theranostic analysis services.

Caris MPI, Inc.

Representative: Anne Fleeson Womble Bond Dickinson (US) LLP, One West Fourth Street, Winston-Salem NC 27101, UNITED STATES OF AMERICA